Pfizer Prevnar vaccine wins approval for ages 6-17

Sat Jan 26, 2013 3:41am IST

Related Topics

Stocks

   

(Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.

The product was already approved in the United States to prevent infections among children aged 6 weeks through 5 years. It is also approved for adults aged 50 and older.

The vaccine protects against infection with 13 strains of the Streptococcus pneumoniae bacterium. The bacterium can cause pneumonia, ear infections and other problems.

Prevnar 13 has annual sales of about $3.5 billion, making it Pfizer's third-biggest brand. It was approved in 2010, and has largely displaced an older vaccine called Prevnar, which protected against only 7 prevalent strains of the bacterium.

(Reporting by Ransdell Pierson; Editing by David Gregorio and Dan Grebler)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

REUTERS SHOWCASE

Fighting Hunger

Fighting Hunger

Hunger easing globally but 1 in 9 people undernourished: report.  Full Article 

Whooping Cough

Whooping Cough

Parents' whooping cough vaccines may protect babies.  Full Article 

Leg Pain

Leg Pain

Chiropractic care may ease back-related leg pain.  Full Article 

Fitness Tip

Fitness Tip

To make the most of a workout, experts say set the proper pace.  Full Article 

E-cigarettes

E-cigarettes

As Big Tobacco takes up e-cigarettes, investors look ahead.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage